Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

September 14, 2024

Anti-Tumor Efficacy of BA3021

January 31, 2023